Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug

Abstract

ABSTRACT Lenalidomide is a key drug in multiple myeloma. Moreover, Al-ZnO has garnered significant attention due to its distinct physicochemical characteristics. This investigation introduces an economic approach for fabrication and characterization of Al-ZnO nanoparticles by SEM, TEM, FT-IR, XPS, UV-VIS, EDS, and XRD techniques. Subsequently, the research explored capacity of the created nanostructure to serve as a nanocarrier for Lenalidomide. Findings indicated an approximate 71% drug loading capacity that is dependent on pH and duration time. The release profile depicted a gradual release under physiological conditions (pH 7.4, 28%), contrasting with a notably accelerated release rate at pH 6.2 (78%) in 48 h. Furthermore, an in vitro assessment of cellular cytotoxicity performed on U266 multiple myeloma cancer cell line to evaluate safety and effectiveness of Al-ZnO nanoparticles. Results from MTT assay affirmed the potential of this nanoparticle as a promising vehicle for Lenalidomide delivery.